Your browser is no longer supported. Please, upgrade your browser.
Settings
LEGN [NASD]
Legend Biotech Corporation
Index- P/E- EPS (ttm)-2.53 Insider Own- Shs Outstand133.00M Perf Week0.98%
Market Cap3.53B Forward P/E- EPS next Y-1.26 Insider Trans- Shs Float127.35M Perf Month0.87%
Income-303.50M PEG- EPS next Q-0.38 Inst Own19.30% Short Float1.77% Perf Quarter-17.53%
Sales75.70M P/S46.59 EPS this Y-122.00% Inst Trans4.10% Short Ratio6.02 Perf Half Y-4.91%
Book/sh2.11 P/B12.66 EPS next Y3.80% ROA-47.30% Target Price- Perf Year-
Cash/sh3.83 P/C6.97 EPS next 5Y- ROE-142.80% 52W Range23.41 - 43.24 Perf YTD-5.11%
Dividend- P/FCF- EPS past 5Y- ROI-107.50% 52W High-38.21% Beta-
Dividend %- Quick Ratio3.70 Sales past 5Y- Gross Margin- 52W Low14.14% ATR1.36
Employees882 Current Ratio3.70 Sales Q/Q-28.80% Oper. Margin- RSI (14)46.18 Volatility4.31% 4.90%
OptionableYes Debt/Eq0.01 EPS Q/Q57.70% Profit Margin- Rel Volume0.32 Prev Close26.03
ShortableYes LT Debt/Eq0.01 EarningsMar 18 BMO Payout- Avg Volume373.74K Price26.72
Recom1.70 SMA20-4.56% SMA50-0.71% SMA200-10.29% Volume122,217 Change2.65%
Jul-01-20Initiated JP Morgan Overweight $50
Jul-01-20Initiated Jefferies Buy $47
Jun-30-20Initiated Morgan Stanley Overweight $55
Mar-18-21 07:00AM  
06:15AM  
Mar-10-21 04:30PM  
Mar-08-21 01:29AM  
Feb-19-21 08:00AM  
Feb-01-21 07:15AM  
Dec-21-20 07:10AM  
Dec-15-20 04:30PM  
Dec-14-20 04:30PM  
08:00AM  
Dec-13-20 08:38AM  
Dec-05-20 03:00PM  
Dec-03-20 08:00AM  
Nov-24-20 08:00AM  
Nov-23-20 07:00AM  
Nov-16-20 07:00AM  
Nov-09-20 11:06AM  
Nov-05-20 07:05AM  
Nov-01-20 10:18AM  
Oct-22-20 05:03PM  
Oct-08-20 09:41PM  
08:21PM  
04:30PM  
Oct-07-20 04:00PM  
03:00PM  
Oct-06-20 11:10PM  
08:10PM  
06:03PM  
08:00AM  
Oct-05-20 04:39PM  
Oct-02-20 02:50PM  
Sep-30-20 06:22PM  
01:40PM  
Sep-29-20 08:00PM  
11:23AM  
Sep-28-20 11:00PM  
04:30PM  
Sep-27-20 01:24AM  
Sep-26-20 04:00PM  
Sep-25-20 02:23PM  
10:00AM  
08:00AM  
Sep-24-20 02:10PM  
11:27AM  
Sep-23-20 11:00PM  
04:38PM  
01:45PM  
08:51AM  
Sep-22-20 07:28PM  
07:00PM  
05:00PM  
01:58PM  
12:53PM  
11:30AM  
Sep-21-20 10:55PM  
09:56PM  
05:44PM  
03:45PM  
01:57PM  
01:39PM  
11:00AM  
09:00AM  
06:30AM  
Sep-08-20 10:20AM  
Sep-01-20 04:00PM  
Aug-28-20 04:34PM  
Aug-05-20 05:37PM  
Aug-02-20 11:02AM  
10:43AM  
Jul-08-20 12:53PM  
Jun-16-20 05:34PM  
Jun-09-20 04:35PM  
04:30PM  
Jun-05-20 05:48PM  
03:45PM  
12:07PM  
08:35AM  
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in North America and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in relapsed and refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates targeting various cancers, including non-hodgkins lymphoma (NHL), acute myeloid leukemia, and T cell lymphoma. In addition, it is developing allogeneic CAR-T product candidates targeting CD20 for the treatment of NHL and targeting B-cell maturation antigen for the treatment of MM, which are currently in an investigator-initiated Phase 1 clinical trial in China. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.